Imbruvica ibrutinib: Preliminary Phase II data

Preliminary data from 5 evaluable patients with relapsed or refractory MCL in the open-label, Australian Phase II AIM trial showed that once-daily 560 mg oral Imbruvica for 4 weeks as induction therapy led

Read the full 339 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE